

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
Ray Goodwin et al.

Attorney Docket No. : 2801-E

Serial No.: 09/151,259

Group Art Unit: 1643

Filed: September 10, 1998

Examiner: Unknown

For: CYTOKINE DESIGNATED 4-1BB LIGAND AND HUMAN RECEPTOR  
THAT BINDS THERETO

INFORMATION DISCLOSURE STATEMENT

BOX NON-FEE

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449. Copies of the publications listed on the attached Form PTO-1449 are not provided because they were cited or submitted to the PTO in connection with application serial nos. 08/060,843, and 08/236,918. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Submission of these publications does not constitute an admission that any are "prior art" under 35 U.S.C. §102 or §103, and Applicants specifically reserve the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method.

To Applicants' knowledge, no office action on the merits has been mailed in the subject application. Thus, no fee is due for the filing of this information disclosure statement.

Respectfully submitted,




Janis C. Henry  
Attorney for Applicant  
Reg. No. 34,347

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone: (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX NON-FEE, Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date indicated below.

Date: November 13, 1998

Signed:   
Camilla C. Edwards

<b>Form PTO-1449</b> U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. <b>2801-E</b>		SERIAL NO. <b>09/151,259</b>			
		APPLICANT <b>Raymond G. Goodwin et al.</b>					
		FILING DATE <b>September 10, 1998</b>		GROUP <b>1643</b>			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,675,285	06/23/87	Clark, et al.	435/6		
		5,030,576	07/09/91	Dull, et al.	435/69		
		5,217,880	6/8/93	Mitta, et al.	435	69.1	3/23/92
		5,312,733	5/17/94	MacLeod	435	69.1	4/11/91
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		Kwon, B. and Weissman, S., "cDNA sequences of two inducible T-cell genes", <i>Proc. Natl. Acad. Sci. USA</i> , 86:1963-1967, March 1989.					
		Kwon, B. et al., "Expression Characteristics of Two Potential T Cell Mediator Genes", <i>Cellular Immunology</i> , 121:414-422, 1989.					
		Kwon, B. et al., "Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones," <i>Proc. Natl. Acad. Sci. USA</i> , 84: 2896-2900, May 1987.					
		Pollok, K. et al., "Inducible T Cell Antigen 4-1BB", <i>The Journal of Immunology</i> , 150: 771-781, February 1, 1993.					
		Mallet, S. and Barclay, A.N., "A new superfamily of cell surface proteins related to the nerve growth factor receptor", <i>Immunology Today</i> , 12:220-223, 1991.					
		Schwartz et al., "cDNA Sequence Tissue Distribution and Regulation of Expression of a New Member of the Human TNF-NGF Receptor Family", <i>Arthritis Rheum.</i> 35 (9 Suppl.), Abstract D63, page S224, 1992.					
		Schwartz et al., "Identification of a New Member of the Human Nerve Growth Factor/Tumor Necrosis Factor Receptor Family," <i>J. Immunology</i> 150: 298A, Abstract No. 1705, 1993.					
		Chalupny, N. et al., "T-cell activation molecule 4-1BB binds to extracellular matrix proteins", <i>Proc. Natl. Acad. Sci. USA</i> , 89:10360-64, November 1992.					
		Flanagan, J. and Leder, P., "The <i>kir</i> Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts", <i>Cell</i> 63:185-194, October 5, 1990					
				DATE CONSIDERED			
EXAMINER							
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>Form PTO-1449</b>		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK		ATTY. DOCKET NO. <b>2801-E</b>	SERIAL NO. <b>09/151,259</b>
OFFICE					
<b>INFORMATION DISCLOSURE CITATION</b>  (Supplemental Sheet)		APPLICANT <b>Raymond G. Goodwin, et al.</b>			
		FILING DATE <b>September 10, 1998</b>		GROUP <b>1643</b>	
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)					
		Aruffo, A. and Seed, B., "Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system", <i>Proc. Natl. Acad. Sci. USA</i> 84: 8573-8577, December 1987			
		Capon, D., et al., "Designing CD4 immunoadhesins for AIDS therapy", <i>Nature</i> 337: 525-531, 9 February 1989			
		Steele, R.E., "Factor hunting made easier", <i>TIBS</i> 16:125-126, April 1991			
		Armitage, R., et al., "Molecular and biological characterization of a murine ligand for CD40", <i>Nature</i> 357: 80-82 (1992)			
		Hollenbaugh, D., et al., "The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity", <i>The Embo Journal</i> 11: 4313-4321 (1992)			
		Ohtsuka, E., et al., "An Alternative Approach to Deoxyoligonucleotides as Hybridization Probes by Insertion of Neoxynosine at Ambiguous Codon Positions," <i>Journal of Biol. Chemistry</i> 260: (5) 2605-2608, 1985			
		Frohman, M., et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," <i>Proc. Natl. Acad. Sci. USA</i> , 85:8998-9002, 1998.			
EXAMINER		DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
Ray Goodwin et al.

Attorney Docket No. : 2801-E

Serial No.: 09/151,259

Group Art Unit: 1646

Filed: September 10, 1998

Examiner: M. Brannock

For: ANTIBODIES TO HUMAN 41-BB RECEPTOR (as amended)

## **INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The material listed on the accompanying Form PTO-1449 is cited in compliance with the provisions of 37 C.F.R. §1.56, 1.97 and 1.98. Copies of each cited reference are enclosed.

Applicants authorize the Commissioner to charge Deposit Account No. 09-0089 the fee set forth in 37 CFR 1.17(p) pursuant to 37 CFR 1.97(c)(2). Kindly acknowledge receipt of this Statement, and make the cited publications of record in the above-identified application.

Respectfully submitted,

Janis C. Henry  
Registration No. 34,347

Immunex Corporation  
51 University Street  
Seattle, Washington 98101  
(206) 587-0430

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: Oct. 12, 2000 Signed: Francis M. Kerton

<b>Form PTO-1449</b> U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO. <div style="text-align: center;">2801-E</div>		SERIAL NO. <div style="text-align: center;">09/151,259</div>			
		APPLICANT <div style="text-align: center;">Raymond G. Goodwin et al.</div>					
		FILING DATE <div style="text-align: center;">September 10, 1998</div>		GROUP <div style="text-align: center;">1646</div>			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b> —							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO
		WO 95/07984	03/23/95	PCT			
		2,108,401	03/28/95	CA			
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the Application of:  
Raymond G. Goodwin, et al.

Docket No.: 2801-E

Serial No.: 09/151,259

Group Art Unit: 1646

Filing Date: September 10, 1998

Examiner: M. Brannock

For: ANTIBODIES TO HUMAN 4-1BB (as amended)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Box AF  
Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications (copies of which are enclosed) are listed on the attached Form PTO-1449. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

The above-cited reference is submitted under § (e)(2), that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The above-cited reference is submitted under §1.97(d) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

  
Paul B. Tran  
Registration No. 41,565

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone (206) 587-0430

